华西虚拟期刊

华西虚拟期刊

查看全文

Synergistic drug combinations enable enhanced therapeutics. Their discovery typically involves the measurement and assessment of drug combination index (CI), which can be facilitated by the development and applications of in-silico CI predictive tools. In this work, we developed and tested the ability of a mathematical model of drug-targeted EGFR-ERK pathway in predicting CIs and in analyzing multiple synergistic drug combinations against observations. Our mathematical model was validated against the literature reported signaling, drug response dynamics, and EGFR-MEK drug combination effect. The predicted CIs and combination therapeutic effects of the EGFR-BRaf, BRaf-MEK, FTI-MEK, and FTI-BRaf inhibitor combinations showed consistent synergism. Our results suggest that existing pathway models may be potentially extended for developing drug-targeted pathway models to predict drug combination CI values, isobolograms, and drug-response surfaces as well as to analyze the dynamics of individual and combinations of drugs. With our model, the efficacy of potential drug combinations can be predicted. Our method complements the developed in-silico methods (e.g. the chemogenomic profile and the statistically-inferenced network models) by predicting drug combination effects from the perspectives of pathway dynamics using experimental or validated molecular kinetic constants, thereby facilitating the collective prediction of drug combination effects in diverse ranges of disease systems.

Key words: EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR; ANTITUMOR-ACTIVITY; ANTICANCER AGENTS; CANCER CELLS; POSITIVE FEEDBACK; BRAF INHIBITION; GENE-EXPRESSION; ACTIVATION; APOPTOSIS

引用本文: . . 华西虚拟期刊, 2000, 1(1): -. doi: 10.1038/srep40752 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,